Gilead Stock News

Declining sales of certain drugs, including coronavirus treatment Veklury, has weighed on Gilead's earnings. Still, Gilead is the world's leader in HIV treatments -- and new products across treatment

The "Halftime Report" traders give their top picks to watch for the second half.

Both of these drugmakers have rich pipelines that will allow them to recover from recent sales slumps. They also offer above-average dividend yields and have raised their payouts regularly over the la

Gilead Sciences stock hasn't been a good investment in recent years, often underperforming the S&P 500. Declining revenue and a lack of a growth catalyst has made investors bearish on the stock.

The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents.

Gilead Sciences saw strong sales growth in the first quarter. While sales were strong, margins took quite a substantial beating.

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations, with weaker demand for its COVID-19 drug weighing on results, sending share

Gilead Sciences reported mixed first-quarter financial results on Thursday afternoon, as sales of its cancer and HIV drugs rose, while sales of its Covid-19 antiviral fell.

Pfizer and Gilead are both facing declines in demand for their coronavirus products. These big-pharma players bring in blockbuster revenue from other products, too -- and the future looks bright.

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Biotech stocks for your late-April 2023 watchlist.

The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U

Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.